Free Trial

Pfizer (PFE) Stock Price, News & Analysis

Pfizer logo
$27.76
-0.33 (-1.17%)
(As of 11/4/2024 ET)

About Pfizer Stock (NYSE:PFE)

Key Stats

Today's Range
$27.73
$28.14
50-Day Range
$27.76
$30.20
52-Week Range
$25.20
$31.54
Volume
40.33 million shs
Average Volume
37.28 million shs
Market Capitalization
$157.31 billion
P/E Ratio
37.51
Dividend Yield
6.05%
Price Target
$33.58
Consensus Rating
Moderate Buy

Company Overview

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

Pfizer Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
100th Percentile Overall Score

PFE MarketRank™: 

Pfizer scored higher than 100% of companies evaluated by MarketBeat, and ranked 4th out of 972 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 5 buy ratings, 8 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pfizer has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to decrease by -1.36% in the coming year, from $2.95 to $2.91 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is 37.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is 37.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.78.

  • Price to Earnings Growth Ratio

    Pfizer has a PEG Ratio of 0.90. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pfizer's valuation and earnings.
  • Percentage of Shares Shorted

    1.25% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 4.91%, indicating that investor sentiment is decreasing.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 5.94%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 15 years.

  • Dividend Coverage

    The dividend payout ratio of Pfizer is 227.03%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 57.73% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • Percentage of Shares Shorted

    1.25% of the outstanding shares of Pfizer have been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 4.91%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Pfizer has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 73 news articles for Pfizer this week, compared to 37 articles on an average week.
  • Search Interest

    Only 211 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.
  • MarketBeat Follows

    94 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 59% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have bought more of their company's stock than they have sold. Specifically, they have bought $28,240.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

The Pfizer logo is displayed at the company's headquarters, Friday, February 5, 2021, in New York
Pfizer rides Paxlovid sales growth to better-than-expected third quarter
A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year
[Urgent] Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.
Image of data processing over black background. Global business and digital interface concept digitally generated image. — Photo
These 3 Stocks Just Spiked—Buy the Rally or Sell the News? (PFE)
Investors received news about three stocks that moved each stock higher, but now investors have to decide whether to buy the rally or take some profits
Wallet with dollars and a blurry Pfizer logo. Pfizer vaccine cost concept against coronavirus, covid-19: NEW YORK, USA, November 30, 2020. — Photo
4 Reasons Pfizer Could Be a Value Play You Can't Miss (PFE)
Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) sent shares surging up to $61.71
Is Pfizer Stock a Bargain for Long-Term Investors?
2 Sensational Growth Stocks to Buy at a Discount
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $28.79 at the beginning of the year. Since then, PFE stock has decreased by 3.6% and is now trading at $27.76.
View the best growth stocks for 2024 here
.

Pfizer Inc. (NYSE:PFE) announced its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The business's revenue was up 31.2% compared to the same quarter last year.
Read the conference call transcript
.

Pfizer subsidiaries include ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others.

Top institutional investors of Pfizer include Van ECK Associates Corp (0.29%), Diamond Hill Capital Management Inc. (0.29%), National Pension Service (0.20%) and Principal Financial Group Inc. (0.16%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol-Myers Squibb (BMY).

Company Calendar

Ex-Dividend for 9/3 Dividend
7/26/2024
Dividend Payable
9/03/2024
Last Earnings
10/29/2024
Today
11/04/2024
Ex-Dividend for 12/2 Dividend
11/08/2024
Dividend Payable
12/02/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/04/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$33.58
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+21.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
15 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
6.49%

Debt

Sales & Book Value

Annual Sales
$60.11 billion
Cash Flow
$2.92 per share
Book Value
$15.81 per share

Miscellaneous

Outstanding Shares
5,666,695,000
Free Float
5,663,295,000
Market Cap
$157.31 billion
Optionable
Optionable
Beta
0.67

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSE:PFE) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners